# Jaguar Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jaguar-health

- Industry: Pharmaceuticals
- Headquarters: San Francisco, US
- Website: www.jaguar.health
- Total disclosed funding: $2M
- Latest round: Series A (Feb 5, 2014)
- Investors on record: 1

## About

Jaguar Health, Inc., based in California, specializes in developing plant-based prescription medicines aimed at addressing unmet medical needs in the gastrointestinal disease sector.Founded in 2013 and headquartered in San Francisco, US, Jaguar Health, Inc. focuses on plant-based pharmaceuticals, primarily targeting gastrointestinal diseases. The company has raised a total of USD 15.00 mn across multiple funding rounds, with the most recent being a Private Placement/Follow on of USD 15.00 mn on January 13, 2021. The CEO, Lisa Conte, has led the company through its strategic initiatives.Jaguar Health specializes in developing and commercializing plant-based prescription medicines for unmet medical needs, particularly in gastrointestinal diseases. Their flagship product, crofelemer, is in phase 3 clinical trials for the prevention of cancer therapy-related diarrhea. The company is also involved in proof-of-concept studies for crofelemer targeting rare diseases like short bowel syndrome and microvillus inclusion disease, with results expected in 2024. Their products serve markets in the United States, European Union, and parts of the Middle East and North Africa, catering to both healthcare providers and patients with chronic GI conditions.In the most recent fiscal year 2024, Jaguar Health reported a revenue of USD 11.69 mn and an EBITDA of USD -28.52 mn. The company's revenue model is primarily based on pharmaceutical product sales, including crofelemer, generated through business-to-business agreements with healthcare providers and institutions.Jaguar Health plans to launch new products, including further developments of crofelemer, which is anticipated to broaden its market reach. The company aims to expand into the European and Middle Eastern markets by 2025. The recent funding of USD 15.00 mn will support these growth initiatives and facilitate the advancement of clinical studies and the expansion of their product pipeline.

## Funding rounds

- Series A, Feb 5, 2014, $2M — BioVeda Capital

## Investors

- BioVeda Capital (https://capitalatlas.ai/funds/bioveda-capital) — Series A